UK Clinical Research Network : Portfolio Database User Guide  
Welcome to the UK Clinical Research Network Study Portfolio  


NB: The information displayed below does not replace the protocol. The latest protocol version should always be consulted before making clinical decisions.
Imaging of patients with psychosis and NMDAR antibodies

A brain imaging study comparing structural and functional brain images in people with psychosis with and without and N-methyl-D-aspartate receptor (NMDAR) antibodies and healthy controls

Specialty
MentalHealth
Portfolio Eligibility
Automatically eligible
ISRCTN
EudraCT
MREC N° 11/EE/0358
UKCRN ID 13300
WHO ID
Research Summary
Study Type Interventional
Design Type Screening
Disease(s) Psychosis
Phase N/A
Current Status In Set-Up NHS Permission Received
Closure Date 8/1/2014
Global Sample Size 45
Geographical Scope Single Centre
Lead Country England
Open to new sites No
Main Inclusion Criteria
All patients with psychosis and autoantibodies to neuronal surface targets.
Patients with psychosis and proven negative serum for autoantibodies will be recruited into the antibody negative group.
Aged 13-60 years.
Patients and control groups will be matched for age, gender and education.
Main Exclusion Criteria
Other CNS disorders, other autoimmune conditions that may explain the presence of antibodies, MRI contraindications, pregnancy.
Chief Investigator(s)
Prof Paul Fletcher
Further details, please contact
Dr Tom Spencer

Cambridgeshire and Peterborough NHS Foundation Trust
-
Cambridge Road
Fulbourn
Cambridge
CB21 5EF
UNITED KINGDOM

tom.spencer@cpft.nhs.uk
Funder(s) Medical Research Council (MRC)
Behavioural and Clinical Neuroscience Institute
Sponsor(s) University of Cambridge
Cambridgeshire and Peterborough NHS Foundation Trust




public.ukcrn.org.uk/search
If you experience problems using the application, please click here.